{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:26Z","timestamp":1788869306295,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019914","name":"Flatiron Health Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:32:38Z","timestamp":1783035158000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-7530","authenticated-orcid":false,"given":"Adam A.","family":"Barsouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Yaskolko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lova","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi Puri","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina E.","family":"Marmarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.07.001_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"10.1016\/j.cllc.2026.07.001_bib0002","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.cllc.2026.07.001_bib0003","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.001_bib0004","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2026.07.001_bib0005","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.001_bib0006","first-page":"630","article-title":"DLL3 expression in small-cell lung cancer: clinicopathological associations and prognostic implications","volume":"18","author":"Dingemans","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"302","key":"10.1016\/j.cllc.2026.07.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.1016\/j.cllc.2026.07.001_bib0008","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer (DeLLphi-301)","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cllc.2026.07.001_bib0009","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study (DeLLphi-300)","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.001_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"suppl 16","key":"10.1016\/j.cllc.2026.07.001_bib0011","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1200\/JCO.2025.43.16_suppl.8088","article-title":"Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer","volume":"43","author":"Parma","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.07.001_bib0012","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.001_bib0013","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cllc.2025.11.018","article-title":"Optimizing tarlatamab delivery in small cell and neuroendocrine lung cancer: real-world insights into step-up dosing and prophylactic tocilizumab use","volume":"27","author":"Joshi","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.07.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109390","article-title":"Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer","volume":"216","author":"Cooper","year":"2026","journal-title":"Lung Cancer"},{"issue":"suppl 16","key":"10.1016\/j.cllc.2026.07.001_bib0015","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1200\/JCO.2026.44.16_suppl.8097","article-title":"Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): a multi-institutional real-world analysis","volume":"44","author":"Fenton","year":"2026","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.001_bib0016","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"key":"10.1016\/j.cllc.2026.07.001_bib0017","article-title":"Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions","volume":"8","author":"Castellanos","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.001_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.cllc.2026.07.001_bib0019","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.001_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2026.07.001_bib0021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.1990.8.9.1563","article-title":"Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base","volume":"8","author":"Albain","year":"1990","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.07.001_bib0022","article-title":"J-TAIL-2: a prospective, observational study of atezolizumab combined with carboplatin and etoposide in patients with extensive-stage SCLC in Japan","volume":"6","author":"Miyauchi","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.001_bib0023","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijrobp.2007.04.036","article-title":"Metabolic tumor burden predicts for disease progression and death in lung cancer","volume":"69","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.001_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab teserine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.07.001_bib0025","doi-asserted-by":"crossref","unstructured":"Davis JA, Dima D, Ahmed N, et al. Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma. Transplant Cell Ther. 30(3):298\u2013305.","DOI":"10.1016\/j.jtct.2023.12.015"},{"key":"10.1016\/j.cllc.2026.07.001_bib0026","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Eng J Med"},{"issue":"8","key":"10.1016\/j.cllc.2026.07.001_bib0027","first-page":"1157","article-title":"Novel therapeutic strategies and targets in small cell lung cancer","volume":"129","author":"Byers","year":"2023","journal-title":"Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:19:23Z","timestamp":1788866363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426000938"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}